People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Evozyne, Inc. | — | Biotechnology | Series C | $144.4M | $979.0M | 2023 |
Matthew M. Rizzo at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Matthew M. Rizzo on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Patrick J. Morris | 1 | 8 |
| Darien J. Parhad | 1 | 7 |
| Antonio J. Gracias | 1 | 7 |
| Jeffrey S. Aronin | 1 | 4 |
| Jude M. Sullivan | 1 | 1 |
| Aleina M. Lee | 1 | 1 |
| Rama J. Ranganathan | 1 | 1 |
| Mike S. Gamson | 1 | 1 |
| Arjun S. Rallapalli | 1 | 1 |
| Antonio S. Gracias | 1 | 1 |
| Aris J. Theologis | 1 | 1 |
| Darien S. Parhad | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.